Andrew Hill

Andrew Hill publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Andrew Hill sits on this spectrum.

Andrew Hill D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew Hill sits on this spectrum.

Overview

Best Publications

• Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis

  Ravindra K Gupta;Michael R Jordan;Binta J Sultan;Andrew Hill

  491
  Citations

• Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis

  Bryony Simmons;Jawaad Saleem;Andrew Hill;Richard D. Riley

  355
  Citations

• Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.

  Ravindra K Gupta;Andrew Hill;Anthony W Sawyer;Alessandro Cozzi-Lepri

  353
  Citations

• Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response

  Bryony Simmons;Jawaad Saleem;Katherine Heath;Graham S. Cooke

  333
  Citations

• CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1 : results of the staccato randomised trial

  Jintanat Ananworanich;Angèle Gayet-Ageron;Michelle Le Braz;Wisit Prasithsirikul

  291
  Citations

• Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

  Andrew Hill;Saye Khoo;Joe Fortunak;Bryony Simmons

  278
  Citations

• A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?

  Victoria Pilkington;Toby Pepperrell;Andrew Hill

  266
  Citations

• Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials

  Ravindra Gupta;Andrew Hill;Anthony W. Sawyer;Deenan Pillay;Deenan Pillay

  251
  Citations

• Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.

  Willem D F Venter;Simiso Sokhela;Bryony Simmons;Michelle Moorhouse

  239
  Citations

• The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

  Jose R Arribas;Andrzej Horban;Jan Gerstoft;Gerdt Fätkenheuer

  221
  Citations

• Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.

  Rebekah L. Puls;Janaki Amin;Marcelo Losso;Praphan Phanuphak

  199
  Citations

• The future role of CD4 cell count for monitoring antiretroviral therapy

  Nathan Ford;Nathan Ford;Graeme Meintjes;Anton Pozniak;Helen Bygrave

  178
  Citations

• Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.

  Brian Barr Godman;Anna Bucsics;Patricia Vella Bonanno;Wija Oortwijn;Wija Oortwijn

  164
  Citations

• The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries.

  Andrew M. Hill;Sanjay Nath;Bryony Simmons

  162
  Citations

• Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.

  Usman Arshad;Henry Pertinez;Helen Box;Lee Tatham

  157
  Citations

• Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

  Ulrik B.Ulrik Dragsted;Jan Gerstoft;Court Pedersen;Barry Peters

  156
  Citations

• Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

  Andrew Hill;Sophie L Hughes;Dzintars Gotham;Anton L Pozniak

  151
  Citations

• The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?

  Marco Vitoria;Andrew Hill;Nathan Ford;Meg Doherty

  135
  Citations

• The Joint United Nations Programme on HIV/AIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture.

  Katherine Heath;Jacob Levi;Andrew Hill

  134
  Citations

• The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.

  J R Arribas;N Clumeck;M Nelson;A Hill

  127
  Citations

• Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.

  Anahita Sadeghi;Ali Ali Asgari;Alireza Norouzi;Zahedin Kheiri

  127
  Citations

• Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial.

  Julie Fox;Barry Peters;Manyu Prakash;Jose Arribas

  123
  Citations

• Rapidly declining HIV infection in MSM in central London.

  Nneka Nwokolo;Andrew Hill;Alan McOwan;Anton Pozniak

  121
  Citations